Literature DB >> 29118087

Overweight and Obesity Are Predictors of Progression in Early Autosomal Dominant Polycystic Kidney Disease.

Kristen L Nowak1, Zhiying You2, Berenice Gitomer2, Godela Brosnahan2, Vicente E Torres3, Arlene B Chapman4, Ronald D Perrone5, Theodore I Steinman6, Kaleab Z Abebe7, Frederic F Rahbari-Oskoui8, Alan S L Yu9, Peter C Harris3, Kyongtae T Bae10, Marie Hogan3, Dana Miskulin5, Michel Chonchol2.   

Abstract

The association of overweight/obesity with disease progression in patients with autosomal dominant polycystic kidney disease (ADPKD) remains untested. We hypothesized that overweight/obesity associates with faster progression in early-stage ADPKD. Overall, 441 nondiabetic participants with ADPKD and an eGFR>60 ml/min per 1.73 m2 who participated in the Halt Progression of Polycystic Kidney Disease Study A were categorized on the basis of body mass index (BMI; calculated using nonkidney and nonliver weight) as normal weight (18.5-24.9 kg/m2; reference; n=192), overweight (25.0-29.9 kg/m2; n=168), or obese (≥30 kg/m2; n=81). We evaluated the longitudinal (5-year) association of overweight/obesity with change in total kidney volume (TKV) by magnetic resonance imaging using linear regression and multinomial logistic regression models. Among participants, mean±SD age was 37±8 years, annual percent change in TKV was 7.4%±5.1%, and BMI was 26.3±4.9 kg/m2 The annual percent change in TKV increased with increasing BMI category (normal weight: 6.1%±4.7%, overweight: 7.9%±4.8%, obese: 9.4%±6.2%; P<0.001). In the fully adjusted model, higher BMI associated with greater annual percent change in TKV (β=0.79; 95% confidence interval [95% CI], 0.18 to 1.39, per 5-unit increase in BMI). Overweight and obesity associated with increased odds of annual percent change in TKV ≥7% compared with <5% (overweight: odds ratio, 2.02; 95% CI, 1.15 to 3.56; obese: odds ratio, 3.76; 95% CI, 1.81 to 7.80). Obesity also independently associated with greater eGFR decline (slope) versus normal weight (fully adjusted β =-0.08; 95% CI, -0.15 to -0.02). In conclusion, overweight and, particularly, obesity are strongly and independently associated with rate of progression in early-stage ADPKD.
Copyright © 2018 by the American Society of Nephrology.

Entities:  

Keywords:  ADPKD; clinical epidemiology; obesity; renal function decline; total kidney volume

Mesh:

Year:  2017        PMID: 29118087      PMCID: PMC5791072          DOI: 10.1681/ASN.2017070819

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  42 in total

Review 1.  Autosomal dominant polycystic kidney disease.

Authors:  Vicente E Torres; Peter C Harris; Yves Pirson
Journal:  Lancet       Date:  2007-04-14       Impact factor: 79.321

2.  Body mass index has no effect on rate of progression of chronic kidney disease in subjects with type 2 diabetes mellitus.

Authors:  Ali Mohsen; Rebecca Brown; Richard Hoefield; Philip A Kalra; Donal O'Donoghue; Rachel Middleton; David New
Journal:  J Nephrol       Date:  2012 May-Jun       Impact factor: 3.902

3.  Body mass index and the risk of development of end-stage renal disease in a screened cohort.

Authors:  Kunitoshi Iseki; Yoshiharu Ikemiya; Kozen Kinjo; Taku Inoue; Chiho Iseki; Shuichi Takishita
Journal:  Kidney Int       Date:  2004-05       Impact factor: 10.612

4.  The HALT polycystic kidney disease trials: design and implementation.

Authors:  Arlene B Chapman; Vicente E Torres; Ronald D Perrone; Theodore I Steinman; Kyongtae T Bae; J Philip Miller; Dana C Miskulin; Frederic Rahbari Oskoui; Amirali Masoumi; Marie C Hogan; Franz T Winklhofer; William Braun; Paul A Thompson; Catherine M Meyers; Cass Kelleher; Robert W Schrier
Journal:  Clin J Am Soc Nephrol       Date:  2010-01       Impact factor: 8.237

5.  Obesity and change in estimated GFR among older adults.

Authors:  Ian H de Boer; Ronit Katz; Linda F Fried; Joachim H Ix; Jose Luchsinger; Mark J Sarnak; Michael G Shlipak; David S Siscovick; Bryan Kestenbaum
Journal:  Am J Kidney Dis       Date:  2009-09-25       Impact factor: 8.860

Review 6.  mTOR Complex1-S6K1 signaling: at the crossroads of obesity, diabetes and cancer.

Authors:  Stephen G Dann; Anand Selvaraj; George Thomas
Journal:  Trends Mol Med       Date:  2007-04-23       Impact factor: 11.951

Review 7.  Association between obesity and kidney disease: a systematic review and meta-analysis.

Authors:  Y Wang; X Chen; Y Song; B Caballero; L J Cheskin
Journal:  Kidney Int       Date:  2007-10-10       Impact factor: 10.612

8.  Tracking kidney volume in mice with polycystic kidney disease by magnetic resonance imaging.

Authors:  D P Wallace; Y-P Hou; Z L Huang; E Nivens; L Savinkova; T Yamaguchi; M Bilgen
Journal:  Kidney Int       Date:  2008-01-09       Impact factor: 10.612

9.  Inhibition of Aerobic Glycolysis Attenuates Disease Progression in Polycystic Kidney Disease.

Authors:  Meliana Riwanto; Sarika Kapoor; Daniel Rodriguez; Ilka Edenhofer; Stephan Segerer; Rudolf P Wüthrich
Journal:  PLoS One       Date:  2016-01-11       Impact factor: 3.240

10.  Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy.

Authors:  Isaline Rowe; Marco Chiaravalli; Valeria Mannella; Valeria Ulisse; Giacomo Quilici; Monika Pema; Xuewen W Song; Hangxue Xu; Silvia Mari; Feng Qian; York Pei; Giovanna Musco; Alessandra Boletta
Journal:  Nat Med       Date:  2013-03-24       Impact factor: 53.440

View more
  39 in total

1.  The value of genotypic and imaging information to predict functional and structural outcomes in ADPKD.

Authors:  Sravanthi Lavu; Lisa E Vaughan; Sarah R Senum; Timothy L Kline; Arlene B Chapman; Ronald D Perrone; Michal Mrug; William E Braun; Theodore I Steinman; Frederic F Rahbari-Oskoui; Godela M Brosnahan; Kyongtae T Bae; Douglas Landsittel; Fouad T Chebib; Alan Sl Yu; Vicente E Torres; Peter C Harris
Journal:  JCI Insight       Date:  2020-08-06

2.  Ketosis Ameliorates Renal Cyst Growth in Polycystic Kidney Disease.

Authors:  Jacob A Torres; Samantha L Kruger; Caroline Broderick; Tselmeg Amarlkhagva; Shagun Agrawal; John R Dodam; Michal Mrug; Leslie A Lyons; Thomas Weimbs
Journal:  Cell Metab       Date:  2019-10-17       Impact factor: 27.287

3.  Long-Term Administration of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease.

Authors:  Marie E Edwards; Fouad T Chebib; Maria V Irazabal; Troy G Ofstie; Lisa A Bungum; Andrew J Metzger; Sarah R Senum; Marie C Hogan; Ziad M El-Zoghby; Timothy L Kline; Peter C Harris; Frank S Czerwiec; Vicente E Torres
Journal:  Clin J Am Soc Nephrol       Date:  2018-07-19       Impact factor: 8.237

Review 4.  Polycystic kidney disease.

Authors:  Carsten Bergmann; Lisa M Guay-Woodford; Peter C Harris; Shigeo Horie; Dorien J M Peters; Vicente E Torres
Journal:  Nat Rev Dis Primers       Date:  2018-12-06       Impact factor: 52.329

5.  Epicardial Fat Thickness in Patients with Autosomal Dominant Polycystic Kidney Disease.

Authors:  Antonio Concistrè; Luigi Petramala; Gianmarco Scoccia; Susanna Sciomer; Valeria Bisogni; Vincenza Saracino; Gino Iannucci; Silvia Lai; Daniela Mastroluca; Gianluca Iacobellis; Claudio Letizia
Journal:  Cardiorenal Med       Date:  2018-05-03       Impact factor: 2.041

6.  Apoptosis and autophagy in polycystic kidney disease (PKD).

Authors:  Kristen L Nowak; Charles L Edelstein
Journal:  Cell Signal       Date:  2019-12-24       Impact factor: 4.315

Review 7.  Recent Advances in the Management of Autosomal Dominant Polycystic Kidney Disease.

Authors:  Fouad T Chebib; Vicente E Torres
Journal:  Clin J Am Soc Nephrol       Date:  2018-07-26       Impact factor: 8.237

Review 8.  Metabolic Reprogramming in Autosomal Dominant Polycystic Kidney Disease: Evidence and Therapeutic Potential.

Authors:  Kristen L Nowak; Katharina Hopp
Journal:  Clin J Am Soc Nephrol       Date:  2020-02-21       Impact factor: 8.237

9.  Patients with Protein-Truncating PKD1 Mutations and Mild ADPKD.

Authors:  Matthew B Lanktree; Elsa Guiard; Pedram Akbari; Marina Pourafkari; Ioan-Andrei Iliuta; Syed Ahmed; Amirreza Haghighi; Ning He; Xuewen Song; Andrew D Paterson; Korosh Khalili; York P C Pei
Journal:  Clin J Am Soc Nephrol       Date:  2021-02-18       Impact factor: 8.237

Review 10.  Strategies to Treat Obesity in Patients With CKD.

Authors:  Kiran Chintam; Alex R Chang
Journal:  Am J Kidney Dis       Date:  2020-10-16       Impact factor: 8.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.